title: Interleukin 6 and C-reactive protein in esophageal cancer.
abstract: Esophageal cancer (EC) is one of the most aggressive malignant tumors of the gastrointestinal tract. It is well known that cancer initiation and tumor development are closely linked with inflammation. C-reactive protein (CRP) and interleukin-6 (IL-6) are acute-phase proteins involved in cancer development. It was suggested that CRP and IL-6 play potential roles in the growth and progression of malignant tumors, including EC. The aim of the study was to describe the significance of IL-6 and CRP in the development of esophageal cancer and to assess the potential role of their serum levels as prognostic indicators of EC patient's survival.
authors.affiliation: Department of Biochemical Diagnostics, Medical University, Waszyngtona 15a, 15-269 Białystok, Poland.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Groblewska
authors.forename: Barbara
authors.initials: B
authors.lastname: Mroczko
authors.forename: Dorota
authors.initials: D
authors.lastname: Sosnowska
authors.forename: Maciej
authors.initials: M
authors.lastname: Szmitkowski
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D004938:Esophageal Neoplasms / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D015870:Gene Expression; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D015850:Interleukin-6 / Q000097:blood*; D011379:Prognosis; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D015850:Interleukin-6; D002097:C-Reactive Protein